Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Meredith A. Hackel"'
Autor:
Mark G. Wise, James A. Karlowsky, Meredith A. Hackel, Mohamed Amine Harti, Bontle M.E. Ntshole, Eva Njeri Njagua, Rita Oladele, Catherine Samuel, Shameema Khan, Jeannette Wadula, Warren Lowman, Busisani W. Lembede, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 35, Iss , Pp 93-100 (2023)
ABSTRACT: Objectives: To report the in vitro susceptibility of Enterobacterales (n = 3905) and Pseudomonas aeruginosa (n = 1,109) isolates, collected from patients in sub-Saharan Africa (four countries) in 2017–2021, to a panel of 10 antimicrobial
Externí odkaz:
https://doaj.org/article/184aa4cc2f9b43c984ce1f17658caf3d
Autor:
Gregory G. Stone, Meredith A. Hackel
Publikováno v:
Annals of Clinical Microbiology and Antimicrobials, Vol 21, Iss 1, Pp 1-9 (2022)
Abstract Background Increases in resistance to fluoroquinolones have been correlated with the use of levofloxacin in the treatment of infections caused by Escherichia coli. The analysis presents the in vitro activity of ceftazidime-avibactam and comp
Externí odkaz:
https://doaj.org/article/69329cc2a18e48abbe0bcfe8edbeeee7
Autor:
James A. Karlowsky, Meredith A. Hackel, Samue l K. Bouchillon, Warren Lowman, Ramy El Mahdy Kotb, Naglaa Mohamed, Gregory G. Stone, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss , Pp 249-256 (2021)
Objectives: To report antimicrobial susceptibility testing surveillance data for ceftaroline and comparative agents from the AWARE global surveillance programme for bacterial pathogens causing skin and soft tissue infections (SSTIs) and lower respira
Externí odkaz:
https://doaj.org/article/a858ccb01d674cd4a09177193d5d3f90
Autor:
Naoki Kohira, Meredith A. Hackel, Yoshino Ishioka, Miho Kuroiwa, Daniel F. Sahm, Takafumi Sato, Hideki Maki, Yoshinori Yamano
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 22, Iss , Pp 738-741 (2020)
Objective: To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4 μg/mL from a multi-national surveillance study. M
Externí odkaz:
https://doaj.org/article/72046124350d4e22babc3f2d708785a5
Autor:
Naoki Kohira, Meredith A Hackel, Merime Oota, Miki Takemura, Fupin Hu, Hiromichi Mizuno, Daniel F Sahm, Yoshinori Yamano
Publikováno v:
Journal of Global Antimicrobial Resistance. 32:181-186
Cefiderocol (CFDC) is a parenteral siderophore cephalosporin that is active against Gram-negative bacteria, including carbapenem-resistant isolates. We report the in vitro activity of CFDC and other antibiotics against 1,738 clinical isolates of Gram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b185a520eaecbba03faebcbe52d4bc75
https://doi.org/10.1016/j.jgar.2022.11.017
https://doi.org/10.1016/j.jgar.2022.11.017
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 21, Iss 3, Pp 343-348 (2017)
Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are important etiologic agents of nosocomial infection that are frequently resistant to broad-spectrum antimicrobial age
Externí odkaz:
https://doaj.org/article/01ab98d884ea4d6793ccb2f869c45615
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Ceftibuten is an established, oral, third-generation cephalosporin in early clinical development in combination with an oral prodrug of avibactam for the treatment of complicated urinary tract infections, including acute pyelonephritis. We evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::084528417fc335b34c8d6a73e87150e4
https://doi.org/10.1128/aac.01346-22
https://doi.org/10.1128/aac.01346-22
Autor:
James A. Karlowsky, Meredith A. Hackel, Mark G. Wise, David A. Six, Tsuyoshi Uehara, Denis M. Daigle, Susan M. Cusick, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales ( n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2db316b6652ae028b33e829665b98779
https://doi.org/10.1128/aac.01281-22
https://doi.org/10.1128/aac.01281-22
Autor:
James A. Karlowsky, Mark G. Wise, Meredith A. Hackel, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Ceftibuten-ledaborbactam etzadroxil is a cephalosporin-boronate β-lactamase inhibitor prodrug combination under development as an oral treatment for complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales producing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73b6bc6b54bf8b87c1f6c07c78b4fa7c
https://doi.org/10.1128/aac.00934-22
https://doi.org/10.1128/aac.00934-22
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat serious Acinetobacter baumannii -calcoaceticus complex (ABC) infections, including carbapenem-non-susceptible and multidrug-resistant (MDR) isolates. The curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::569188f90cbb50c274048aefb9baf3c3
https://doi.org/10.1128/aac.00781-22
https://doi.org/10.1128/aac.00781-22